The long-duration action of levodopa may be due to a postsynaptic effect

Clinical Neuropharmacology

Volumn 20, Issue 5, 1997, Pages 394-401

  Barbato, Luca ^a   Stocchi, Fabrizio ^a,b,c   Monge, Alessandra ^a   Vacca, Laura ^c   Ruggieri, Stefano ^b,c   Nordera, Giampietro ^a   Marsden, C David ^a,d  

^a Istituto Antonio Benedetti   (Italy)

^b Mediterranean Institute of Neuroscience   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Levodopa; Long duration action; PD; Ropinirole

Indexed keywords

ANTIPARKINSON AGENT; CARBIDOPA PLUS LEVODOPA; DOMPERIDONE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; LEVODOPA; ROPINIROLE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; MALE; MOTOR PERFORMANCE; MULTICENTER STUDY; NEUROLOGIC DISEASE; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PHYSICAL DISABILITY; PRIORITY JOURNAL; RATING SCALE; TREATMENT OUTCOME;

EID: 0030752606     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199710000-00003     Document Type: Article

References (20)

1. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino-acides and modification of parkinsonism. New Engl J Med 1967;276:374-9.
2. Muenter MD, Tyce GM. L-DOPA therapy of PD in plasma L-DOPA concentration, therapeutic response, and side effects. Mayo Clin Proc 1971;46:231-9.
3. Kaye JA, Feldman RG. The role of L-DOPA holiday in the long term management of Parkinson's disease. Clin Neuropharmacol 1986;9:1-13.
4. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
5. Fahn S, Elton RL. Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M. eds. Recent developments in Parkinson's disease. Vol II. Florham Park, NJ: Macmillan Healthcare Information, 1987;153-63, 293-304.
6. Hoehn MM, Elton RL, Low dosages of bromocriptine added to levodopa in Parkinson's disease. Neurology 1985;35:199-206.
7. Stocchi F, Quinn NP, Barbato L, et al. Comparison between a fast and slow release preparation of levodopa and a combination of the two: A clinical and pharmacokinetic study. Clin Neuropharmacol 1994;17:38-44.
8. Eden RJ, Costall B, Domeney AM, et al. Preclinical pharmacology of ropinirole (SK & F 101468A) a novel dopamine D2 agonist. Pharmacol Biochem Behav 1991;38:147-54.
9. Rascol O, Lees AJ, Senard JM, et al. A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients. Adv Neurol 1996;69:531-4.
10. Ogasahara S, Nishikawa Y, Takahashi M, et al. Dopamine metabolisn in the central nervous system after discontinuation of L-DOPA therapy in patients with Parkinson's disease. J Neurol Sci 1984;66:151-63.
11. Nutt JG, Carter JH, Woodward WR. Long-duration response to levodopa. Neurology 1995;45:1613-6.
12. Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 1986;49:853-60.
13. Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease: Imposing pharmacological law and order. Ann Neurol 1996;39:561-73.
14. Doller HJ, Connor JD. Changes in neostriatal dopamine concentrations in response to levodopa infusions. J Neurochem 1980;341:1264-9.
15. Lloyd KG, Davidson L, Hornykiewicz O. Metabolism of levodopa in the human brain. Adv Neurol 1973; 3:173-188.
16. Lloyd KG, Davidson L, Hornykiewicz O. The neurochemistry of Parkinson's disease: Effect of l-DOPA therapy. J Pharmacol Exp Ther 1975;195:453-64.
17. Quattrone A, Zappia M. Oral pulse levodopa therapy in mild Parkinson's disease. Neurology 1993;43:1161-6.
18. Quattrone A, Zappia M, Aguglia U, et al. The subacute levodopa test for evaluating long-duration response in Parkinson's disease. Ann Neurol 1995;38:389-95.
19. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN. Wearing-off fluctuations in Parkinson's disease:contribution of postsynaptic mechanisms. Ann Neurol 1994;36:27-31.
20. Colosimo C, Merello M, Hughes AJ, Sieradzan K, Lees AJ. Motor responses to acute dopaminergic challenge with apomorphine and levodopa in Parkinson s disease: implication for the pathogenesis of the on-off phenomenon. J Neurol Neurosurg Psychiatr 1996;61:634-7.